Summary of evidence and Expert Committee recommendations
The Expert Committee recommended the removal of lamivudine + zidovudine 150 mg + 300 mg from the EMLc to be in alignment with the recommendations of the Inter-Agency Task Team on Prevention and treatment of HIV in Pregnant Women, Mothers and their Children (1).
1. Update to the optimal list of paediatric ARV formulations. IATT Meeting Report, Geneva, Switzerland, 11-12 September 2013 Geneva: World Health Organization; 2013. Available from: http://apps.who.int/medicinedocs/documents/s21435en/s21435en.pdf.